semaglutide fda approval mash Approves Wegovy for Liver Disease Treatment | Jennifer D Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP posted on the topic mash and glp 1 GLP-1

Central role of SUMOylation in the regulation of chromatin interactions and transcriptional outputs of the androgen receptor in prostate cancer cells

In August 2025 , Wegovy became the first GLP-1 therapy approved to treat non-cirrhotic MASH (liver disease)

Eli Lillys tirzepatide drug, marketed as Mounjaro, reported a 12% sales increase to 136 crore in May, remaining the largest-selling therapy in the segment

Its side-effect column describes variable results including loss of efficacy and rebound appetite, and its guidance column says to contact your provider immediately if that happens

Semaglutide or Tirzepatide for Type 2 Diabetes Both of the medications are highly used to manage type 2 diabetes